MA22866A1 - Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . - Google Patents

Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .

Info

Publication number
MA22866A1
MA22866A1 MA23157A MA23157A MA22866A1 MA 22866 A1 MA22866 A1 MA 22866A1 MA 23157 A MA23157 A MA 23157A MA 23157 A MA23157 A MA 23157A MA 22866 A1 MA22866 A1 MA 22866A1
Authority
MA
Morocco
Prior art keywords
treatment
neuro
compounds
preparation
degenerative disorders
Prior art date
Application number
MA23157A
Other languages
English (en)
Inventor
Conrad Griffith Ronald
Balestra Michael
John Murray Robert
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of MA22866A1 publication Critical patent/MA22866A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MA23157A 1992-04-03 1993-04-02 Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . MA22866A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number Publication Date
MA22866A1 true MA22866A1 (fr) 1993-12-31

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23157A MA22866A1 (fr) 1992-04-03 1993-04-02 Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .

Country Status (28)

Country Link
EP (1) EP0633879B1 (fr)
JP (2) JP3120810B2 (fr)
KR (1) KR100259567B1 (fr)
CN (1) CN1044367C (fr)
AT (1) ATE163925T1 (fr)
AU (2) AU3897693A (fr)
CA (1) CA2133427C (fr)
CZ (1) CZ288519B6 (fr)
DE (1) DE69317411T2 (fr)
DK (1) DK0633879T3 (fr)
DZ (1) DZ1677A1 (fr)
ES (1) ES2115055T3 (fr)
FI (1) FI105025B (fr)
HU (1) HU211529A9 (fr)
IL (1) IL105276A (fr)
MA (1) MA22866A1 (fr)
MX (1) MX9301935A (fr)
MY (1) MY110149A (fr)
NO (1) NO302170B1 (fr)
NZ (1) NZ251384A (fr)
PL (1) PL180014B1 (fr)
RU (1) RU2128650C1 (fr)
SG (1) SG47948A1 (fr)
SK (1) SK281258B6 (fr)
TW (1) TW282455B (fr)
UA (1) UA29437C2 (fr)
WO (1) WO1993020052A1 (fr)
ZA (1) ZA932415B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0356035B1 (fr) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
MXPA02000927A (es) * 1999-07-28 2003-07-14 Johnson & Johnson Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos.
WO2007017652A2 (fr) * 2005-08-10 2007-02-15 Astrazeneca Ab Utilisation therapeutique
EP2391606A4 (fr) * 2008-12-24 2012-06-13 Astrazeneca Ab Composés d'éthanamine et leur application pour le traitement de la dépression
WO2013088135A1 (fr) 2011-12-14 2013-06-20 Astrazeneca Ab Diagnostic de gabr-a2
DK3066091T3 (da) * 2013-11-05 2019-07-15 Astrazeneca Ab Nmda-antagonist-prodrugs
MX2022016183A (es) * 2020-06-23 2023-02-13 Biohaven Therapeutics Ltd Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320006A3 (fr) * 1987-12-11 1990-12-19 Laboratoires Syntex Utilisations de 1,4-dihydropyridines
EP0356035B1 (fr) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice

Also Published As

Publication number Publication date
EP0633879B1 (fr) 1998-03-11
DK0633879T3 (da) 1998-09-28
NO302170B1 (no) 1998-02-02
FI944546L (fi) 1994-09-30
RU2128650C1 (ru) 1999-04-10
MY110149A (en) 1998-02-28
NO943645D0 (no) 1994-09-30
CN1081669A (zh) 1994-02-09
UA29437C2 (uk) 2000-11-15
AU3897693A (en) 1993-11-08
IL105276A (en) 1997-06-10
ES2115055T3 (es) 1998-06-16
FI105025B (fi) 2000-05-31
DE69317411T2 (de) 1998-07-30
PL180014B1 (pl) 2000-11-30
HK1009331A1 (en) 1999-05-28
JP3120810B2 (ja) 2000-12-25
CN1044367C (zh) 1999-07-28
ATE163925T1 (de) 1998-03-15
KR100259567B1 (ko) 2000-07-01
MX9301935A (es) 1994-08-31
FI944546A0 (fi) 1994-09-30
JP2000319259A (ja) 2000-11-21
RU94042465A (ru) 1996-07-20
NZ251384A (en) 1996-10-28
SG47948A1 (en) 1998-04-17
TW282455B (fr) 1996-08-01
IL105276A0 (en) 1993-08-18
CZ240994A3 (en) 1995-12-13
SK281258B6 (sk) 2001-01-18
ZA932415B (en) 1993-10-22
CZ288519B6 (cs) 2001-07-11
CA2133427C (fr) 2003-06-10
SK117794A3 (en) 1995-05-10
CA2133427A1 (fr) 1993-10-14
WO1993020052A1 (fr) 1993-10-14
HU211529A9 (en) 1995-11-28
EP0633879A1 (fr) 1995-01-18
DE69317411D1 (de) 1998-04-16
NO943645L (no) 1994-11-16
JPH07505385A (ja) 1995-06-15
DZ1677A1 (fr) 2002-02-17
AU705419B2 (en) 1999-05-20
AU7545696A (en) 1997-02-13

Similar Documents

Publication Publication Date Title
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
EP0668750A4 (fr) Vis pediculaire et appareillage de correction de la colonne par l'approche posterieure.
MA22626A1 (fr) Procede de preparation d'acides imidazolyl-alcenoiques .
FR2690855B1 (fr) Adsorbants pour l'elimination de hcl et procede pour leur production et leur utilisation.
MA26410A1 (fr) Formulations pharmaceutiques et procede pour leur production.
BG101118A (en) Therapeutical compounds
FR2740132B1 (fr) Procede pour la preparation de 1,1,1,3,3-pentafluoropropane
MA22866A1 (fr) Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .
EP0673384A4 (fr) Polypeptides utiles pour traiter des troubles inflammatoires.
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
MA23134A1 (fr) Procede pour la preparation d'aryl-piperidine carbinols .
CA2217513A1 (fr) Agents pharmaceutiques pour le traitement de la maladie d'alzheimer
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires
FR2700956B1 (fr) Composition cosmetique et pharmaceutique et procede pour sa preparation.
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
MA23081A1 (fr) Procede de preparation de derives d'indolone
MA23953A1 (fr) Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites
FR2677354B1 (fr) Procede pour la preparation d'esters d'acides racemisables.
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
FR2673635B1 (fr) Procede pour la preparation d'une composition aerosol.
FR2736635B1 (fr) Procede de preparation d'alpha,omega-bromochloroalcanes
FR2696171B1 (fr) Procede de preparation du divinylbenzene.
FR2676583B1 (fr) Procede pour la desorption d'iode de fission.
FR2702769B1 (fr) Nouveau procede de preparation d'alkylpolyosides faiblement colores.